Nutlin-3

製品コードS1061

Nutlin-3化学構造

分子量(MW):581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

サイズ 価格(税別)  
JPY 30710.00
JPY 18260.00
JPY 28220.00
JPY 61420.00
JPY 161020.00

カスタマーフィードバック(4)

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
ターゲット
Mdm2 [5]
(Cell-free assay)
180 nM
体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\CVXVqPcLizszN MYW0POKhcA>? NX3IOJJG[myxY3vzJFI4NU:KQz3pcoR2[2WmIHPlcIwheHKxbHnm[ZJifGmxbjDjc41x[XKjYnzlJJRwKHSqYYSgc4Yh[mG|YXygcIV3\Wy| M4r5R|I3OzVyNU[1
NP69 M32zTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHpTWM2OD1|MT62PeKyOi53NDFOwG0> NGmxRW0zPjJ3MkW3OS=>
NP460 M4PZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTJ{Lki1xtEyNjF6IN88US=> NFfTUZIzPjJ3MkW3OS=>
C666-1 NIXkUHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fJS2lEPTB;MUmuPVXDuThwOUOg{txO MmrGNlYzPTJ3N{W=
C666-1 MlPhR4VtdCCYaXHibYxqfHliQYPzZZk> NWDE[XM1OTBiwsXN MmLaOFghcA>? NIL2OYZFVVOR M1zMV5NmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJJRp\SCleYTveI95cWNiZX\m[YN1KG:oIHPpd5Bt[XSrbh?= MnjUNlYzPTJ3N{W=
C666-1  Mon3SpVv[3Srb36gRZN{[Xl? M{L2ZlExKML3TR?= NVHyXIxYOjRiaB?= MWjEUXNQ NX[2dnlp[WO2aY\heIV{KHSqZTDwOVMheGG2aIfhfUwhfXC{ZXf1cIF1cW6pIIC1N{wheDJzIHHu[EBO\G1{ NUDtc2NjOjZ{NUK1O|U>
C666-1 MV\BdI9xfG:|aYOgRZN{[Xl? MYmxNEDDvU1? MofBOFgwPzJiaB?= M4W3Z2ROW09? M3j4WpNmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJINqe3CuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NXrsV|dsOjZ{NUK1O|U>
A549 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DsOVI1KGh? NUDmPYZ6UUN3ME2xO{43QCEEsTC0MlUzKM7:TR?= M2m5OlI3OTJ3MkOw
A549-NTC NUHQTZN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXiyOEBp MYXJR|UxRTF7LkSyJOKyKDFwOU[g{txO M4faeVI3OTJ3MkOw
A549-920 M3zEOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPJNlQhcA>? MWjJR|UxRTN|Lki1JOKyKDRwOESg{txO NVP2VZpFOjZzMkWyN|A>
CRL-5908 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3D[|g6OjRiaB?= MYnJR|UxRTN6LkexJOKyKDJwNEOg{txO NWm0XodDOjZzMkWyN|A>
L6 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzpZpAyOMLizszNxsA> Mo[xNlQwPDhxN{KgbC=> MXXEUXNQ MWTpcohq[mm2czDj[YxteyCycn;sbYZmemG2aX;uJIFv\CCmaX\m[ZJmdnSrYYTpc44> NFjRWYIzPTh5MUe5OC=>
C2C12 MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDNNVDDqM7:TdMg NVXRXGRjOjRxNEivO|IhcA>? NFvrSGZFVVOR NFPUWmhqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? NUnSXVQ6OjV6N{G3PVQ>
MCF-7  M{HrV2Z2dmO2aX;uJGF{e2G7 MlS3NVDDqM7:TR?= Moi3SG1UVw>? MV\pcohq[mm2czDjfYNtcW5iREGgZY5lKESrY3XyxsA> MoLVNlU4ODJ5MEO=
DU4475  NVG1NZZHTnWwY4Tpc44hSXO|YYm= MV21M|ExNzJyIN88US=> NEO1UYUzPMLiaB?= MnvN[I94dnKnZ4XsZZRmeyCWb3PhMVEh\G:|ZTDk[ZBmdmSnboTsfS=> MnHkNlU2PDdzN{S=
SMMC-7721 MYrGeY5kfGmxbjDBd5NigQ>? NVTybo17OTBizszN NXO0fGcxPDhiaB?= NF35eXBFVVOR MULjZZV{\XNiRF7BJGRUSiCmYX3h[4U> NH;5cJozPTV2NEO2NS=>
SMMC-7721 NHS1V|ZHfW6ldHnvckBCe3OjeR?= NHG5T28yOCEQvF2= MlHKOFghcA>? NHTHeXVFVVOR M3H5TIlv\HWlZYOgeIhmKGOqcn;tZZRqdi2kb4Xu[EBxem:2ZXnuJGlHUTF4IITvJJBienSrYXzsfUBtd2OjbHn6[UBqdiC2aHWgZ5l1d3CuYYPtxsA> NWO2SG1NOjV3NESzOlE>
SMMC-7721 MoD1SpVv[3Srb36gRZN{[Xl? M4L4UlExKM7:TR?= NIH3[2Q1QCCq Mne3SG1UVw>? Mly4bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:owrDJSm5DOcLibWLORS=> MnjwNlU2PDR|NkG=
SMMC-7721 NIL6coNHfW6ldHnvckBCe3OjeR?= NFzybogyOCEQvF2= MlPDN|YhcA>? MlTFSG1UVw>? M3nZfoNifXOnczD0bIUh\WO2b4DpZ{BmgHC{ZYPzbY9vKG:oIFnGTVE3 MnHvNlU2PDR|NkG=
MCF-7 MYnGeY5kfGmxbjDBd5NigQ>? MX[xNOKh|ryP M3THN|AuOjRiaB?= NHP5e2xqdmS3Y3XzJJA2OyCjbnSgdFIyN0OrcEG= MVuyOVQ5OjN5Mx?=
OVCAR10 MXrGeY5kfGmxbjDBd5NigQ>? MmLRNVDDqM7:TR?= M33sbFIycMLi MWXEUXNQ MmXUbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> MljpNlU1OjZ3NEi=
NCI-H23 M1TiWmZ2dmO2aX;uJGF{e2G7 MWGxNOKh|ryP NYW4PG1oOjGqwrC= MVfEUXNQ MmDqbY5kemWjc3XzJJA2OyCycn;0[YlvKGyndnXsdy=> M13RTVI2PDJ4NUS4
A2780 NUDWfpJ2TnWwY4Tpc44hSXO|YYm= MorQNVDDqM7:TR?= MVGyNYjDqA>? MkLpSG1UVw>? M3q2W4lv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> NF3WcW4zPTR{NkW0PC=>
NCI-H23 MULGeY5kfGmxbjDBd5NigQ>? MV:xNOKh|ryP M1XSVVIycMLi MlPSSG1UVw>? MoHG[IVkemWjc3XzJJRp\SCIb4jNNUBt\X[nbIO= NGr1ZmkzPTR{NkW0PC=>
A2780 MoexSpVv[3Srb36gRZN{[Xl? MnjBNVDDqM7:TR?= NU[4OpdDOjGqwrC= MorzSG1UVw>? M2DpXoRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz MVOyOVQzPjV2OB?=
HCT116  MVzGeY5kfGmxbjDBd5NigQ>? M4PBNFExKML3TR?= NFy0N5QzPCCq M3rHb4NifXOnczDhJJA2Oy2mZYDlcoRmdnRidHX0doFxdG:rZDDHNU1ienKnc4SgbY4h\GmybH;p[EBJS1RzMU[gZ4xwdmW|IFSzJIFv\CCGOB?= MVeyOVM5ODB3NR?=
MCF-10CA1a MVjGeY5kfGmxbjDBd5NigQ>? M2ri[lExyqEQvF2= NUXJ[I5wPDhiaB?= MXLEUXNQ NGHTN5RqdmirYnn0d{Bj[XOjbDDpcpZie2mxbjDhcoQhemWmdXPl[EBVT0ZvzsKzMYlv\HWlZXSgbY53[XOrb36geI8h[mG|YXygcIV3\Wy| M3\Fc|I2OjV5N{K5
MCF-10A1  M2TPXmZ2dmO2aX;uJGF{e2G7 MXyxNOKh|ryP NI\aSnEzPC92ODDo NG\nb|lFVVOR NXrDPHE2cW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi MmqwNlUzPTd5Mkm=
MCF-10CA1a MlLUSpVv[3Srb36gRZN{[Xl? MmruNVDDqM7:TR?= NV;L[WRGOjRiaB?= MWPEUXNQ NGrTbFll\WO{ZXHz[ZMhfGinIGTHSk3PujNvaX7keYNm\CCvUl7BJIxmfmWuczDv[m1OWDJuwrDNUXA6NCCjbnVCpIlvfGWpcnnuxsDPusLiMx?= NVf1WJJSOjV{NUe3Nlk>
MCF-10CA1a NUnDfoVDTnWwY4Tpc44hSXO|YYm= NFHqZpYyOMLizszN Moq5NlQhcA>? MnXRSG1UVw>? MnfNbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w MoTNNlUzPTd5Mkm=
SK-BR-7 NEPvOHVHfW6ldHnvckBCe3OjeR?= MnHqNVDDqM7:TR?= Ml7kNlQhcA>? NV;IPG1sTE2VTx?= NY\hN4xbcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NEP3NY0zPTJ3N{eyPS=>
SUM102PT M{nFSGZ2dmO2aX;uJGF{e2G7 NVixem1xOTEEoN88US=> MlnpNlQhcA>? NHvPOJpFVVOR MVvpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? M17kcFI2OjV5N{K5
RAW 264.7 M4C2N2Z2dmO2aX;uJGF{e2G7 NGK3eFYyOMLizszN M1XRXFMxKG2rbh?= M3fkeZBz\X[nboTzJJRp\SCyNUOgdoVlfWO2aX;uJIlvKHKnc4DvcpNmKHSxIFzQVy=> M4TQ[|I2OTd{NUS3
RAW 264.7 MWfGeY5kfGmxbjDBd5NigQ>? Mm\mNVDDqM7:TR?= NFHFeY8{OCCvaX6= MnHUdoVlfWOnczD0bIUhVFCVLXH1[41mdnSnZDD0bIUhVkZvzsrCJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhZ5Rqfmm2eR?= MXKyOVE4OjV2Nx?=
RAW 264.7 Mn\XSpVv[3Srb36gRZN{[Xl? NYLtOmJvOTEEoN88US=> M1LVNFMxKG2rbh?= MnT5bY5pcWKrdIOgUHBUNWmwZIXj[YQhVk9icILv[JVkfGmxbtMg MmDSNlUyPzJ3NEe=
MCF7  NGnKSY5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkKzNk42KML3TR?= MX61JIQ> MULEUXNQ M2fYSJNmdnOrdHn6[ZMhVUOINzD0c{BRSVKSIHnubIljcXSrb36= MnmzNlUxQDV7MEK=
MCF7  NFfXfFZHfW6ldHnvckBCe3OjeR?= M3;iPVIvPSEEtV2= M3nl[lQ5KGh? MXnEUXNQ NUC4VmRu\GWlcnXhd4V{KHSqZTDoc41wdG:pb4XzJGRUSiC{ZYDhbZIh\nKncYXlcoNq\XN? Ml75NlUxQDV7MEK=
ACHN NHXLVZpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MkHKNE42NTFyIN88US=> MmHaNE03KGR? NXOzcWtQTE2VTx?= NEDLN5dqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1m2clI2ODZ5N{i3
Caki-2 NUHhSJQ3S2WubDDWbYFjcWyrdImgRZN{[Xl? NFjuXYMxNjVvMUCg{txO MnPPNE03KGR? NH[2cHVFVVOR MnKybY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NULuT2s2OjVyNke3PFc>
A498 M2LXUmNmdGxiVnnhZoltcXS7IFHzd4F6 NX3LfnU{OC53LUGwJO69VQ>? NHy3VZAxNTZiZB?= NHXWS4xFVVOR MWHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M{DSVVI2ODZ5N{i3
115 M1vrNmNmdGxiVnnhZoltcXS7IFHzd4F6 NFfIWG0xNjVvMUCg{txO MWOwMVYh\A>? NH:4bmtFVVOR MkLpbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MnP5NlUxPjd5OEe=
117 NVzxN|llS2WubDDWbYFjcWyrdImgRZN{[Xl? NIDuNIYxNjVvMUCg{txO NXLQcZRZOC14IHS= Mlf5SG1UVw>? NXz4WVZvcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MknBNlUxPjd5OEe=
ACHN MmmwSpVv[3Srb36gRZN{[Xl? NH3BZ|ExNjVxMT:1JO69VQ>? MXy0PEBp NIrzTVZFVVOR NXHtbVZOdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= NFyxOJgzPTB4N{e4Oy=>
Caki-2 M37VU2Z2dmO2aX;uJGF{e2G7 M3rW[lAvPS9zL{Wg{txO MXK0PEBp NUPhUHpkTE2VTx?= M4PoXoxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz MmXPNlUxPjd5OEe=
A498 NGX3[2xHfW6ldHnvckBCe3OjeR?= NF;qV4kxNjVxMT:1JO69VQ>? MUi0PEBp NV\w[YlVTE2VTx?= MnjEcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? Ml\4NlUxPjd5OEe=
115 M1;mXWZ2dmO2aX;uJGF{e2G7 MYmwMlUwOS93IN88US=> M2LobFQ5KGh? MVPEUXNQ NVTXUYZzdGWjZIOgeI8hcW6lcnXhd4VlKGW6cILld5Nqd25ib3[gdFU{KGGwZDDzc41mKHB3MzD0ZZJo\XRiZ3Xu[ZM7KE2GTUKsJIFv\CCyMkG= MkPqNlUxPjd5OEe=
ACHN Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nOd|Uh|ryP MlPsOFghcA>? Mlf4SG1UVw>? NIfXU5BqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> MWeyOVA3Pzd6Nx?=
Caki-2 NXrwcZBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLxWlc2KM7:TR?= NVPKcnBRPDhiaB?= MlLWSG1UVw>? Mn7PbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MY[yOVA3Pzd6Nx?=
A498 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;hVGl[PSEQvF2= Mor5OFghcA>? NF3HVpJFVVOR MnLLbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg NWjQfVhoOjVyNke3PFc>
115 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVK1JO69VQ>? M2LkOFQ5KGh? MYrEUXNQ MmKxbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MWOyOVA3Pzd6Nx?=
ACHN Mkn5SpVv[3Srb36gRZN{[Xl? MYS1JO69VQ>? M1;LcFQ5KGh? NVu0dnRtTE2VTx?= M4TLdolv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= M1vGPFI2ODZ5N{i3
Caki-2 M4n2cWZ2dmO2aX;uJGF{e2G7 MUK1JO69VQ>? NXHCSlV5PDhiaB?= NVPxR2kxTE2VTx?= NYTUfGNYcW6mdXPld{BxPTNvZHXw[Y5l\W62IIPlcoV{[2WwY3ZCpC=> MlzjNlUxPjd5OEe=
A498 NWXMc2dDTnWwY4Tpc44hSXO|YYm= NWL2cJF7PSEQvF2= MYq0PEBp M4DpUGROW09? MmDObY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= MlK2NlUxPjd5OEe=
115 NXnZOYJ2TnWwY4Tpc44hSXO|YYm= MmjYOUDPxE1? MkjROFghcA>? Mk\oSG1UVw>? NGrRXI1qdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg M4fkTlI2ODZ5N{i3
MOLM-13 MVXGeY5kfGmxbjDBd5NigQ>? NInKOpY3yqEQvF2= NVHrZ2I2OC16IHi= NW[zb3RoTE2VTx?= MmDDbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZicEWzMEBOTE1{LDDwNlEh[W6mIHHj[ZR6dGG2ZXSgdFU{ MmjXNlQ5QDVyOEK=
MOLM-13 MmXoSpVv[3Srb36gRZN{[Xl? M{XTbVbDqM7:TR?= MVq2JIg> MVjEUXNQ MlPB[Y5p[W6lZYOgeIhmKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFJDKGGwZDDo[YF1KHOqb3PrJJBzd3SnaX7zJGh{eDJ5IHHu[EBJe3B7MB?= MVeyOFg5PTB6Mh?=
HepG2 NVfWem5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L2eFczKGh? MYXEUXNQ NXvofHAzUUN3ME2zOU45PiEEsTCyMlkh|ryP NWfmSVB7OjR6OES4NFk>
HepG2/As NHHoV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnwO|IhcA>? NGPNcZNFVVOR Mk\PTWM2OD14OD6xN{DDuSB7Lk[g{txO NH;0XI0zPDh6NEiwPS=>
SMMC7721 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1foXlczKGh? M1j4OmROW09? MorvTWM2OD1|MT6yPEDDuSB2LkKg{txO NV3tS4Z2OjR6OES4NFk>
SMMC7721/Ac MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVO3NkBp NH25N3dFVVOR M4DZNWlEPTB;NUWuNlEhyrFiNT6wN{DPxE1? Mm\INlQ5QDR6MEm=
Huh-7 MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HKZlczKGh? MlPHSG1UVw>? M2n3OGlEPTB;M{OuPVYhyrFiMz65JO69VQ>? NGLvZ5MzPDh6NEiwPS=>
Hep3B M1TVZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:xV3dlPzJiaB?= NEXwc3NFVVOR NVe1bJE2UUN3ME2yNE4yQCEEsTCxMlg1KM7:TR?= NXq1dJN[OjR6OES4NFk>
HepG2 M4C2TmFxd3C2b4Ppd{BCe3OjeR?= MlP3bY5lfWOnczDhdI9xfG:|aYO= MXOyOFg5PDhyOR?=
SMMC7721 NGS4[YZCeG:ydH;zbZMhSXO|YYm= M{Ds[Ilv\HWlZYOgZZBweHSxc3nz MlHsNlQ5QDR6MEm=
Huh-7 NHzYUlBCeG:ydH;zbZMhSXO|YYm= MWPpcoR2[2W|IHHwc5B1d3Orcx?= NXr1bIM4OjR6OES4NFk>
Hep3B MoDRRZBweHSxc3nzJGF{e2G7 MVLpcoR2[2W|IHHwc5B1d3Orcx?= NYe4XVU6OjR6OES4NFk>
U2OS  NFv1XZlHfW6ldHnvckBCe3OjeR?= NYHM[IpLOjBizszN MXyyOEBp NXPPbHZMcW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQlPMNmEyNCCEQ1zYUOKh[W6mQlPMWy=> MkXINlQ5Pjd{NUm=
AML2 NIXMeIlCeG:ydH;zbZMhSXO|YYm= NXTSS4d{Oi9zMDFOwG0> MXSyOE81QCCq NHHsVndqdmS3Y3XzJIFxd3C2b4Ppdy=> Ml[2NlQ3PTl5NEm=
MOML13 NH7D[lhCeG:ydH;zbZMhSXO|YYm= MXmyM|ExKM7:TR?= M{HuVVI1NzR6IHi= MlzObY5lfWOnczDhdI9xfG:|aYO= MWCyOFY2QTd2OR?=
AML2 MV\GeY5kfGmxbjDBd5NigQ>? NVnjfW9FOTEQvF2= NYnRc4N2Oi92IHi= NID4RZlqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> MUCyOFY2QTd2OR?=
AML3 MV7GeY5kfGmxbjDBd5NigQ>? MUSxNO69VQ>? MmftNk81KGh? MUfpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= Mm\SNlQ3PTl5NEm=
MOML13 NFK4WJlHfW6ldHnvckBCe3OjeR?= MYixNO69VQ>? MYSyM|QhcA>? NH7QeFZqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> M4PLVVI1PjV7N{S5
BeWo NIe3S2FHfW6ldHnvckBCe3OjeR?= NIPDUnM{OCEEtV2= MUCyOEBp M4LydYlv[3KnYYPld{BxPTNuIF3kcVItKHB{MTDhcoQhWHWvYTDheEB1cGVicILveIVqdiCuZY\lcC=> NILFOlYzPDR7OEG1OC=>
BeWo MVPBdI9xfG:|aYOgRZN{[Xl? MoPMN|AhyrWP NGPPOFczPCCq M{n2colv[3KnYYPld{BieG:ydH;zbZM> NIrqUpIzPDR7OEG1OC=>
OCI MonESpVv[3Srb36gRZN{[Xl? M2TDS|ExKM7:TR?= NE\BTFUzPCCq MW\1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? NWD0Tm9KOjR2N{O1OlI>
MOLM M2HJUGZ2dmO2aX;uJGF{e2G7 NUSxTG9TOTBizszN M2e5V|I1KGh? MYn1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? Mn\PNlQ1PzN3NkK=
U2OS  NIPLRopHfW6ldHnvckBCe3OjeR?= MUCyNEDPxE1? NFv3e4IzPCCq Mn3abY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZidHjlJGhQNTFicILveIVqdiCjczD3[YxtKGG|IITo[UBxPTNicILveIVqdg>? NInoe2gzPDN4NkCwOy=>
RKO MUHGeY5kfGmxbjDBd5NigQ>? NVXycYV1OjBizszN MXWyOEBp M2C4eIlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? NXnEd4dZOjR|Nk[wNFc>
U2OS  NXrxXnhSTnWwY4Tpc44hSXO|YYm= MWCyNEDPxE1? MWeyOEBp NETtPXVqdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> NVr5dJJ7OjR|Nk[wNFc>
RKO NHjIUWtHfW6ldHnvckBCe3OjeR?= NISyclgzOCEQvF2= NX7tXoZkOjRiaB?= M1;tSYlv\HWlZYOgTG8uOSCneIDy[ZN{cW:wIHH0JJRp\SCuZY\lcEBw\iC2cnHud4NzcXC2aX;u MXSyOFM3PjByNx?=
SMMC-7721  MX;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGnZcowyNjJ3LUKwJO69VQ>? NVPNeXRvOjRxNEivO|IhcA>? NFjqfYJFVVOR MYLpcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NETG[|YzPDJ6NkOxNi=>
HuH-7 MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUCxMlI2NTJyIN88US=> NEC5TZIzPC92OD:3NkBp MnLsSG1UVw>? NEjTOm9qdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NWnLRYM6OjR{OE[zNVI>
SMMC-7721  M2HvWGFxd3C2b4Ppd{BCe3OjeR?= NFfY[YozOCEQvF2= M{XlV|Q5KGh? M{OwSGROW09? MWfpcoR2[2W|IHHwc5B1d3Orcx?= M1rCeVI1Ojh4M{Gy
HuH-7 MXfBdI9xfG:|aYOgRZN{[Xl? MYeyNEDPxE1? MWm0PEBp NVraSZpuTE2VTx?= MlLsbY5lfWOnczDhdI9xfG:|aYO= MXiyOFI5PjNzMh?=
SMMC-7721  MV3GeY5kfGmxbjDBd5NigQ>? NFPlb|EyOCEQvF2= MmXhN|YhcA>? NVXtW2NUTE2VTx?= M{\aZoRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ MW[yOFI5PjNzMh?=
HuH-7 M2fkemZ2dmO2aX;uJGF{e2G7 NVzHWmZUOTBizszN MVKzOkBp MYPEUXNQ NGH0OIJld3ewLYLl[5Vt[XSnczD0bIUheHKxdHXpckBmgHC{ZYPzbY9vKGyndnXsJI9nKHCqb4PwbI8uW2W{M{myMZA2Ow>? NVW1WY5iOjR{OE[zNVI>
AT2 MYLGeY5kfGmxbjDBd5NigQ>? M2nTclUwOTBizszN Mlf5cIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? Ml3nNlQzPDB{MEO=
REH NXLQc5pYTnWwY4Tpc44hSXO|YYm= NGDuWG42NzFyIN88US=> NYLhVWhZdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= MnixNlQzPDB{MEO=
UoCB6 M{nqOWZ2dmO2aX;uJGF{e2G7 MlO5OU8yOCEQvF2= M{nsTYxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li M3;ZdVI1OjRyMkCz
AT2 NX3qWVdTS2WubDDWbYFjcWyrdImgRZN{[Xl? MVmwMVI2KM7:TR?= NHPXV2pqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M2T0[VI1OjRyMkCz
REH MUHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUfIfXRxOC1{NTFOwG0> MY\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NYTVRXcyOjR{NECyNFM>
UoCB6 M3vYe2NmdGxiVnnhZoltcXS7IFHzd4F6 M1PlWlAuOjVizszN MnS3bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M4DLT|I1OjRyMkCz
A2780 MYPGeY5kfGmxbjDBd5NigQ>? NGTqR4k2NzFyL{KwJO69VQ>? Mn35NlQhcA>? MmTLeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? NEXzbIMzPDF|NkG0Oy=>
H460 M33MRmZ2dmO2aX;uJGF{e2G7 M3HXT|UwOTBxMkCg{txO M33xRlI1KGh? M{DuXJVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi MkXHNlQyOzZzNEe=
Lovo  MoHBSpVv[3Srb36gRZN{[Xl? MYW1M|ExNzJyIN88US=> MX6yOEBp NV3iW2M1fXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= NHrn[G4zPDF|NkG0Oy=>
A2780 NIGyenNCeG:ydH;zbZMhSXO|YYm= NGDGOVc2NzFyL{KwJO69VQ>? MX6yOEBp NWrHNYNs\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? M4\YdVI1OTN4MUS3
H460 MYnBdI9xfG:|aYOgRZN{[Xl? NV3NZWRPPS9zMD:yNEDPxE1? NUPtW|BMOjRiaB?= MU\lcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> NXTDTFhCOjRzM{[xOFc>
Lovo  M1z1TWFxd3C2b4Ppd{BCe3OjeR?= NIPpcXg2NzFyL{KwJO69VQ>? NG[w[YYzPCCq MVzlcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> MlHLNlQyOzZzNEe=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験:

[1]

+ 展開
  • 細胞株: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度: Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間: 8, 24, and 48 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 製剤: Formulated in 2% Klucel, 0.5% Tween 80
  • 投薬量: 200 mg/kg
  • 投与方法: Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4

CAS No. 890090-75-2
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Mdm2シグナル伝達経路

相関Mdm2製品

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID